LON:AGY

Allergy Therapeutics Interim Earnings Results & Report

Allergy Therapeutics logo
GBX 1.31 -0.14 (-9.86%)
As of 09:55 AM Eastern

Allergy Therapeutics reported Interim earnings on March 31, 2026. The company reported EPS of -GBX 0.38, while revenue was £36.28 million.

Earnings Announcement Details

Quarter
Interim
Report Date

Allergy Therapeutics EPS Results

Actual EPS
-GBX 0.38
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Allergy Therapeutics Revenue Results

Actual Revenue
£36.28 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Allergy Therapeutics Interim Earnings FAQ

Allergy Therapeutics (LON:AGY) reported earnings of -GBX 0.38 per share for Interim. The report was announced on Tuesday, March 31, 2026.

Allergy Therapeutics reported revenue of £36.28 million for Interim.

Allergy Therapeutics Earnings Headlines

Allergy Therapeutics plc Announces Board Resignations
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
Allergy Therapeutics to go private
See More Allergy Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Allergy Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Allergy Therapeutics and other key companies, straight to your email.

About Allergy Therapeutics

Allergy Therapeutics (LON:AGY) is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group has achieved over 9% compound annual growth since formation and employs c.500 employees.

View Allergy Therapeutics Profile